Category
Neuroprotection
Peptides studied for their ability to protect neurons from ischemic damage, excitotoxicity, and neurodegenerative processes. This category overlaps with cognitive enhancement but focuses specifically on disease-state neuroprotection rather than healthy cognition optimization.
13 peptides in this category
What are neuroprotective peptides?
Neuroprotective peptides are compounds that reduce neuronal death or dysfunction in the context of brain injury or neurodegenerative disease. Semax protects neurons from ischemic damage by upregulating BDNF and suppressing apoptotic pathways. Cerebrolysin, a peptide mixture, has demonstrated efficacy in multiple clinical trials for Alzheimer's disease and stroke recovery. These peptides generally act through growth factor signaling (BDNF, NGF), mitochondrial protection, or anti-inflammatory mechanisms rather than the receptor antagonism used in conventional neuroprotective drug strategies.
Neurodegeneration and acute brain injury involve overlapping but distinct mechanisms. In acute ischemia, neurons die from energy failure, excitotoxic glutamate release, and oxidative stress within hours of blood flow interruption. In chronic neurodegeneration (Alzheimer's, Parkinson's, ALS), the timeline is years to decades, with protein aggregation, mitochondrial dysfunction, and neuroinflammation as primary drivers. Peptides studied for neuroprotection must therefore be evaluated against the specific injury context — a compound protective in stroke models may have no relevance to Alzheimer's pathology, and vice versa.
Semax's neuroprotective properties are well-studied in ischemic contexts, where its BDNF-upregulating effects appear to reduce penumbral neuron death and improve functional recovery. Cerebrolysin, a defined mixture of neuropeptides from porcine brain protein hydrolysis, is approved in Russia, China, and several European countries for ischemic stroke and Alzheimer's disease, and has completed multiple randomized controlled trials. Dihexa, a hepatocyte growth factor system modulator, shows remarkably potent pro-cognitive and neuroprotective effects in animal models at nanomolar concentrations, with a mechanism distinct from BDNF-pathway peptides.
Compounds
Peptides in this category
Anserine
PreclinicalBeta-Alanyl-N-methyl-L-histidine
Anserine is a methylated dipeptide analog of carnosine found in high concentrations in avian and fish muscle. It shares carnosine's pH-buffering and antioxidant properties but shows superior blood-brain barrier penetration. Research highlights potential for cognitive decline prevention, reduction of amyloid-beta toxicity, and improved exercise performance. It is often studied alongside carnosine for synergistic effects.
Cerebrolysin
ApprovedFPF 1070
Cerebrolysin is a mixture of neuropeptides and neurotrophic factors derived from porcine brain proteins. It mimics the actions of endogenous neurotrophic factors (NGF, BDNF, CNTF), promoting neuronal survival, synaptogenesis, and neuroplasticity. Approved in multiple countries for Alzheimer's disease, stroke recovery, and TBI, clinical trials show improvements in cognitive function, activities of daily living, and brain MRI outcomes.
Cortagen
PreclinicalAla-Glu-Asp-Pro · AEDP
Cortagen is a synthetic tetrapeptide (Ala-Glu-Asp-Pro) characterized as a cortex cytoprotective peptide in research from the St. Petersburg Institute. It penetrates the blood-brain barrier and is reported to regulate neuronal gene expression, protect cortical neurons, and improve cognitive function in aging models. It is often studied alongside other peptide bioregulators from the same research group.
Cortexin
ApprovedCortexin polypeptide complex
Cortexin is a polypeptide complex derived from the cerebral cortex of calves or pigs, containing a mixture of neuropeptides and neurotrophic factors. Approved in Russia for stroke, TBI, epilepsy, and cognitive disorders, it exhibits neuroprotective, nootropic, and anticonvulsant properties. Research supports improvements in cognitive function, reduced neurological deficit after stroke, and accelerated recovery from brain injury. It is conceptually similar to Cerebrolysin but derived from cortical tissue.
Dihexa
PreclinicalN-hexanoic-Tyr-Ile-(6) aminohexanoic amide · PNB-0408
Dihexa is a small peptide derived from angiotensin IV that acts as a potent agonist at the HGF/c-Met receptor system, which mediates synaptogenesis — the formation of new synaptic connections. Animal studies suggest it may be several orders of magnitude more potent than BDNF at promoting synapse formation. Research focuses on Alzheimer's disease, cognitive decline, and traumatic brain injury.
Exenatide
ApprovedByetta · Bydureon
Exenatide is a GLP-1 receptor agonist derived from exendin-4, a peptide found in Gila monster saliva. The first GLP-1 RA approved for type 2 diabetes, it established the GLP-1 drug class. Extended-release formulations (Bydureon) allow once-weekly dosing. Emerging research explores repurposing for Parkinson's disease, where small trials show motor improvement, and Alzheimer's disease neuroprotection.
Humanin
PreclinicalHN · mitochondria-derived peptide humanin
Humanin is a 21-amino-acid mitochondria-derived peptide (MDP) encoded within the 16S rRNA gene of mitochondrial DNA. It is cytoprotective against Alzheimer's-related neuronal death, reduces oxidative stress, improves insulin sensitivity, and suppresses apoptosis through multiple pathways (STAT3, IGFBP-3, FPRL1). Circulating humanin levels decline with age, linking it to age-related diseases.
NAP
Phase IIDavunetide · NAPVSIPQ
NAP (NAPVSIPQ) is an 8-amino-acid neuroprotective peptide derived from activity-dependent neuroprotective protein (ADNP). It stabilizes microtubules by interacting with tubulin, protecting neurons against tau pathology, amyloid toxicity, and oxidative damage. Phase 2 trials in schizophrenia and progressive supranuclear palsy have been completed; research is ongoing for Alzheimer's disease and autism spectrum disorder.
Noopept
ApprovedN-phenylacetyl-L-prolylglycine ethyl ester · GVS-111
Noopept is a dipeptide-derived nootropic approved in Russia for cognitive disorders and memory impairment. It is hydrolyzed in vivo to release cycloprolylglycine, an endogenous neuropeptide. Research demonstrates neuroprotective, memory-enhancing, and anxiolytic effects, upregulation of BDNF and NGF in the hippocampus and cortex, and potential benefits in Alzheimer's disease models. It is significantly more potent than piracetam on a weight-for-weight basis.
P21
PreclinicalP21 cognitive peptide
P21 is a peptide fragment derived from CNTF (Ciliary Neurotrophic Factor) designed to activate the STAT3 signaling pathway, which promotes neurogenesis and cognitive function. Animal research demonstrates improved spatial memory, increased hippocampal neurogenesis, and enhanced BDNF expression. It is studied as a non-cytokine CNTF functional mimetic without the systemic side effects of full-length CNTF.
Pinealon
PreclinicalEDR peptide · Glu-Asp-Arg
Pinealon is a synthetic tripeptide (Glu-Asp-Arg) developed by the St. Petersburg Institute of Bioregulation and Gerontology. It is characterized as a pineal gland cytoprotective peptide that penetrates the blood-brain barrier and acts as a transcription factor, regulating gene expression in neuronal cells. Research suggests neuroprotective, antioxidant, and cognition-preserving effects, particularly in aging and hypoxic conditions.
Semax
ApprovedMEHFPGP · Pro8-Gly9-Pro10-ACTH(4–10)
Semax is a synthetic heptapeptide analog of ACTH(4-7) developed in Russia, where it is approved for stroke, TBI, peptic ulcers, and cognitive enhancement. It upregulates BDNF and its receptor TrkB, promotes dopamine and serotonin turnover, and has demonstrated neuroprotective effects in ischemia models. Research highlights improvements in attention, memory, and recovery from neurological injury.
TRH
ApprovedThyrotropin-Releasing Hormone · Thyroliberin
TRH is a tripeptide (pGlu-His-Pro-NH2) produced in the hypothalamus that stimulates TSH and prolactin release from the anterior pituitary. Beyond thyroid regulation, TRH has direct CNS effects — it is alerting, antidepressant, neuroprotective, and anticonvulsant. Research explores TRH analogs (taltirelin, approved in Japan) for ALS, spinal cord injury, Alzheimer's disease, and treatment-resistant depression, avoiding thyroid side effects.
Research applications
What researchers are studying
Ischemic stroke recovery
Semax administered intranasally within hours of experimental ischemia reduces infarct volume and improves neurological function scores in rat stroke models. Human clinical data from Russia support its use as an adjunct in acute ischemic stroke, with studies showing improved neurological outcomes versus standard care alone. The drug is registered in Russia and Ukraine for this indication.
Neurodegenerative disease modification
Cerebrolysin has completed over 20 randomized controlled trials across Alzheimer's disease, vascular dementia, and stroke recovery. Meta-analyses show modest but consistent improvements in cognitive and clinical global assessments. The proposed mechanism involves upregulation of NGF and BDNF, synaptic stabilization, and reduction of amyloid precursor protein processing — though the exact active components within the complex mixture remain partly uncharacterized.
Excitotoxicity and oxidative stress protection
BDNF-upregulating peptides protect neurons against glutamate-induced excitotoxicity by activating TrkB receptors that suppress pro-apoptotic signaling and maintain mitochondrial membrane potential. This mechanism is relevant to multiple injury types including traumatic brain injury, hypoxia, and the oxidative stress component of neurodegenerative disease.
Want the full research picture?
Full peptide profiles include mechanism details, study data, dosing research, and sourcing.